Skip to main content
S&P 5007,610.34+0.32%DOW52,028.07-0.12%NASDAQ26,153.23+0.66%BTC$75,823.00-0.63%ETH$2,399.06-1.94%GOLD$4,386.20+1.23%OIL$103.57-2.14%
Smart Investors Daily
GH

NASDAQ · GH

Guardant Health, Inc.

Healthcare · Medical - Diagnostics & Research

$175.65

Up+$7.81 (+4.65%)

Updated Sep 16, 2026, 12:52 PM

SID Score

6.7/10

Composite research score

Smart Money

54/100

Neutral

Market cap
12.58B
P/E ratio
-31.72
Dividend yield
0.00%
52-week range
$53.40 – $176.58
Volume
2.85M
Avg. volume
2.66M

Price performance

GH price history

1M range · 0 trading sessions · Daily adjusted prices

GH does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest GH news

The latest Smart Investors Daily articles mentioning GH.

Stock researchCompany · Overview

GH research

Overview

Company profile and research snapshot.

Company profile

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$93.00
Implied upside
—
Analysts
—
GH recent ratings
DateFirmRatingTarget
Sep 9, 2026UBSBuy—
Sep 8, 2026Rothschild & CoBuy—
Sep 2, 2026BTIGBuy—
Aug 4, 2026Piper SandlerOverweight—
Aug 4, 2026Stephens & Co.Overweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

PALO ALTO, Calif., September 09, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes at the 2026 World Conference on Lung Cancer (WCLC). The conference is hosted by the International Association for the Study of Lung Cancer (I

Yahoo · Sep 8, 2026

Business Insider Names Guardant Health One of America's Most Innovative Businesses

PALO ALTO, Calif., September 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider’s America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category.

Yahoo · Sep 8, 2026

What Makes Guardant Health (GH) a Compelling Bet?

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By